Author

J. K. Richer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 8 Approach:experimental assay· 6 Assay:bulk RNA-seq· 5 Research Focus:cancer & tumor microenvironment· 4 Research Focus:differential expression· 4 Approach:statistical model· 4 Research Focus:cell type annotation· 3 Assay:proteomics· 2

Frequent Co-Authors

J. Gertz· 3 shared S. Oesterreich· 3 shared Z. Li· 3 shared A. Bahreini· 2 shared A. Clauset· 2 shared A. V. Lee· 2 shared B. G. Bitler· 2 shared J. M. Atkinson· 2 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Gertz

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinoma

L. B. Van Kleunen, M. Ahmadian, M. D. Post, R. J. Wolsky, C. Rickert, K. Jordan, J. Hu, J. K. Richer, N. A. Marjon, K. Behbakht, M. J. Sikora, B. G. Bitler, A. Clauset

The paper uses spatial data from ovarian cancer tumors to show that spatial organization of the immune microenvironment correlates with patient outcomes and can predict treatment response.

bioRxiv · Jan 26, 2024Cancer Biology

RUNX1 is regulated by androgen receptor to promote cancer stem markers and chemotherapy resistance in triple negative breast cancer.

N. B. Fernandez, S. M. Sosa, J. T. Roberts, M. S. Recouvreux, L. Rocha-Viegas, J. L. Christenson, N. S. Spoelstra, F. L. Couto, A. R. Raimondi, J. K. Richer, N. Rubinstein

This study shows that RUNX1 is regulated by androgen receptor in TNBC, promoting cancer stem cell markers and chemotherapy resistance.

bioRxiv · Nov 12, 2022Cancer Biology

NPC1 confers metabolic flexibility in Triple Negative Breast Cancer

K. I. O'Neill, L.-W. Kuo, M. M. Williams, H. T. Lind, L. S. Crump, N. G. Hammond, N. S. Spoelstra, M. C. Caino, J. K. Richer

This study identifies NPC1 as a key driver of metabolic flexibility and aggressiveness in TNBC, showing its role in cholesterol homeostasis and therapeutic vulnerability.

bioRxiv · May 5, 2022Cancer Biology

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis

Z. Li, Y. Wu, M. E. Yates, N. Tasdemir, A. Bahreini, J. Chen, K. M. Levine, N. M. Priedigkeit, S. Ali, L. Buluwela, S. Arnesen, J. Gertz, J. K. Richer, B. Troness, D. El-Ashry, , S. Oesterreich

This study identifies ESR1 mutations as drivers of breast cancer metastasis by altering cell adhesion and migration through genomic and transcriptomic reprogramming.

bioRxiv · Feb 10, 2021 · PreprintCancer Biology

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

Z. Li, Y. Wu, A. Bahreini, N. M. Priedigkeit, K. Ding, C. A. Sartorius, L. Miller, M. Rosenzweig, N. Wagle, J. K. Richer, W. J. Muller, L. Buluwela, S. Ali, Y. Fang, L. Zhu, , S. Oesterreich

This study shows ESR1 mutant breast cancers exhibit basal cytokeratin expression and immune activation, linked to chromatin reprogramming and paracrine signaling.

bioRxiv · Dec 29, 2020 · PreprintCancer Biology

The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval

K. R. Jordan, M. J. Sikora, J. E. Slansky, A. Minic, J. K. Richer, M. R. Moroney, J. C. Costello, A. Clauset, K. Behbakht, T. R. Kumar, B. G. Bitler

This study identifies an IL-6/IER3 inflammatory signaling axis linked to chemo-resistance in ovarian cancer by analyzing pre- and post-chemotherapy tumor microenvironment changes.

Clinical Cancer Research · Dec 1, 2020Peer-reviewedCancer Biology

Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance

L. S. Crump, G. L. Wyatt, T. R. Rutherford, J. K. Richer, W. W. Porter, T. R. Lyons

This study identifies SEMA7A as a driver of therapeutic resistance in ER+ breast cancer and suggests targeting survival signaling pathways as a potential treatment strategy.

bioRxiv · Oct 5, 2020Cancer Biology

Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and through secondary effects

S. Arnesen, Z. Blanchard, M. M. Williams, K. C. Berrett, Z. Li, S. Oesterreich, J. K. Richer, J. Gertz

This study shows that ER mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects, not just ligand independence.

bioRxiv · Apr 8, 2020Cancer Biology